Clinical implications of diverse calcification patterns in endovascular therapy for femoral-popliteal arterial occlusive disease
Journal of Vascular Surgery · 2024
DOI: 10.1016/j.jvs.2024.01.205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Vascular Surgery, 2024. Verfasst von Bingchen Hou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, The First Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Femoral Artery, Popliteal Artery, Peripheral Arterial Disease, Vascular Patency. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Liaoning Provincial Natural Science Foundation, China Medical University, National Natural Science Foundation of China.
Abstract (Originalsprache)
OBJECTIVE: The aim of this study was to investigate whether intimal arterial calcification (IAC) and medial arterial calcification (MAC) are correlated with the various clinical outcomes following endovascular therapy (EVT) for peripheral arterial disease (PAD). METHODS: This single-center retrospective study comprised 154 consecutively hospitalized individuals with PAD who underwent EVT for de novo femoral-popliteal calcific lesions from January 2016 to July 2021. The predominant calcification patterns of IAC and MAC were assessed using a semi-quantitative computed tomography scoring system. The Kaplan-Meier method and Cox regression were conducted to evaluate the correlations between calcification patterns and medium- to long-term outcomes. RESULTS: The distribution of calcification patterns was as follows: IAC in 111 patients (72%) and MAC in 43 patients (28%). No remarkable variation was noted between the IAC and MAC groups regarding age (P = .84) and gender (P = .23). The MAC group indicated lower rates of 4-year primary patency, assisted primary patency, secondary patency, and amputation-free survival (AFS) compared with the IAC group (24% ± 7% vs 40% ± 6%; P = .003; 30% ± 8% vs 51% ± 6%; P = .001; 51% ± 8% vs 65% ± 5%; P = .004; and 43% ± 9% vs 76% ± 5%; P < .001, respectively). There was no significant difference in the rate of freedom from clinically driven target lesion revascularization between the MAC and IAC groups (63% ± 10% vs 73% ± 5%; P = .26). Stepwise multivariable Cox regression analysis demonstrated that MAC was associated with poor patency (hazard ratio, 1.81; 95% confidence interval, 1.12-2.93; P = .016) and AFS (hazard ratio, 2.80; 95% confidence interval, 1.52-5.16; P = .001). CONCLUSIONS: Compared with IAC, MAC is independently associated with lower medium- to long-term patency and AFS after EVT for de novo femoral-popliteal occlusive lesions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Vascular Surgery, The First Hospital of China Medical University, Shenyang, China.
- Department of Vascular Surgery, The First Hospital of China Medical University, Shenyang, China. Electronic address: jianzhang@cmu.edu.cn.
Förderung
- Liaoning Provincial Natural Science Foundation
- China Medical University
- National Natural Science Foundation of China
Zitieren
APA
Hou, B., Gang, Q., Li, X., Lun, Y., Jiang, H., Shen, S., Xin, S., & Zhang, J. (2024). Clinical implications of diverse calcification patterns in endovascular therapy for femoral-popliteal arterial occlusive disease. Journal of Vascular Surgery. https://doi.org/10.1016/j.jvs.2024.01.205
Vancouver
Hou B, Gang Q, Li X, Lun Y, Jiang H, Shen S, et al. Clinical implications of diverse calcification patterns in endovascular therapy for femoral-popliteal arterial occlusive disease. Journal of Vascular Surgery. 2024. doi:10.1016/j.jvs.2024.01.205
BibTeX
@article{Hou2024,
author = {Hou, Bingchen and Gang, Qingwei and Li, Xinyang and Lun, Yu and Jiang, Han and Shen, Shikai and Xin, Shijie and Zhang, Jian},
title = {Clinical implications of diverse calcification patterns in endovascular therapy for femoral-popliteal arterial occlusive disease},
journal = {Journal of Vascular Surgery},
year = {2024},
doi = {10.1016/j.jvs.2024.01.205}
}
EUVIMED